Michael Gütschow

Prof. Michael Gütschow is a Professor at the Pharmaceutical Institute of the University of Bonn. His research focuses on designing tailored inhibitors for proteases involved in cancer, viral infections (e.g., SARS-CoV-2), and developing proteolysis-targeting chimeras (PROTACs) for targeted protein degradation. He leads projects in drug discovery, including antiviral agents and epigenetic therapies.

His work spans protease inhibition mechanisms, activity-based probes for enzyme analysis, and novel drug modalities like PROTACs for cyclin-dependent kinases and cereblon. Notable collaborations include studies on CDK6 degraders for multiple myeloma and SARS-CoV-2 main protease inhibitors.

Recent publications highlight advancements in histone deacetylase degraders, NLRP3 inflammasome modulation, and USP7-targeting PROTACs. His research bridges biochemistry, medicinal chemistry, and translational medicine, contributing to innovative therapeutic strategies.